Bicara Therapeutics Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2022 | — | $-98.8M | $4.2M |
| FY2023 | — | $-148.8M | $230.4M |
| FY2024 | — | $491.9M | $489.7M |
| FY2025 | — | $401.5M | $96.7M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2022 | — | $-98.8M | $4.2M |
| FY2023 | — | $-148.8M | $230.4M |
| FY2024 | — | $491.9M | $489.7M |
| FY2025 | — | $401.5M | $96.7M |